Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05 2024 - 7:00AM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene
therapy company focused on developing and commercializing AAV-based
gene therapies for the treatment of monogenic diseases of the
central nervous system (CNS), today announced that, on January 2,
2024, Taysha's Board of Directors granted Meredith Schultz, M.D.,
M.S., an option to purchase 257,700 shares of the Company's common
stock in connection with her employment as Taysha’s new Senior Vice
President, Clinical Development and Medical Affairs. The stock
option was granted under the Taysha Gene Therapies, Inc. 2023
Inducement Plan as an inducement material to Ms. Schultz entering
into employment with Taysha in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock option has an exercise price of $1.71 per share, which
is equal to the closing price of Taysha's common stock on the date
of grant. The stock option has a 10-year term and will vest over
four years, with 25% of the option vesting on the first anniversary
of the vesting commencement date and the remaining 75% of the
option vesting in equal monthly installments over the 36 months
thereafter. Vesting of the stock option is subject to such
employee's continued service to Taysha on each vesting date.
About Taysha Gene TherapiesTaysha Gene
Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS
disease. With a singular focus on developing curative medicines, we
aim to rapidly translate our treatments from bench to bedside. We
have combined our team’s proven experience in gene therapy drug
development and commercialization with the world-class UT
Southwestern Gene Therapy Program. Together, we leverage our fully
integrated platform with a goal of dramatically improving patients’
lives. More information is available at www.tayshagtx.com.
Company Contact:Hayleigh Collins Director, Head
of Corporate Communications and Investor RelationsTaysha Gene
Therapies, Inc.hcollins@tayshagtx.com
Media Contact:Carolyn HawleyCanale
Communicationscarolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Sep 2023 to Sep 2024